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Abstract Patients co-infected with HIV-1 and tuberculosis
(TB) are at risk of developing TB-associated immune reconsti-
tution inflammatory syndrome (TB-IRIS) following com-
mencement of antiretroviral therapy (ART). TB-IRIS is charac-
terized by transient but severe localized or systemic inflamma-
tory reactions against Mycobacterium tuberculosis antigens.
Here, we review the risk factors and clinical management of
TB-IRIS, as well as the roles played by different aspects of the
immune response in contributing to TB-IRIS pathogenesis.
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HIV-tuberculosis co-infection
Human immunodeficiency virus type 1 (HIV-1) and Myco-
bacterium tuberculosis are two major infectious diseases and
each was responsible for causing approximately 1.5 million
deaths in 2013 [1, 2]. There were an estimated 9.0 million
cases of active tuberculosis (TB) in 2013, among which about
1.1million (13%)were HIV-1 co-infected [2]. The prevalence
of HIV-1 co-infection among TB cases is the highest in Africa,
accounting for around 78 % of the total HIV-TB cases.
HIV-1 infection and active TB disease individually lead to
severe immune impairment and they can also exacerbate the
disease progression and pathology of one another. Tuberculo-
sis can cause lymphocytopenia in the absence of HIV-1 or
other cause of immunodeficiency [3, 4]. When CD4+ T cells
counts were controlled for, HIV-1 patients with active TB
disease still have more a rapid course of disease progression
and poorer survival rate than those without active TB [5].
Furthermore, people living with HIV-1 are 26–31 times more
likely to develop TB than HIV-uninfected individuals [6].
HIV-1 causes functional disruption of the immune response
and impairs the host’s ability to controlM. tuberculosis infec-
tion via several mechanisms (reviewed in [7]). Firstly, HIV-1
replication is higher in stimulated macrophages at the site of
M. tuberculosis infection [8, 9], and higher viral loads in bron-
choalveolar lavage and in pleural fluid have been observed
[10, 11]. Secondly, HIV-1-infected macrophages have reduced
secretion of TNF-α that associates with reduced apoptosis in
response to M. tuberculosis [12, 13]. While expression of
TLR2 and TLR4 are preserved in HIV-1-infected macro-
phages, TNF-α secretion in response to specific TLR ago-
nists, as well as signal transduction through IRAK-1 and
NF-κB nuclear translocation, are significantly reduced [13].
Finally, HIV-1 infects and depletes CD4+ T cells, including
those that are M. tuberculosis-specific, resulting in decreased
production of IFN-γ, TNF-α and other cytokines that are im-
portant in controlling both pathogens [14–18].
Several interventions have been implemented to address
the syndemics of HIV-1 and TB. These include routine HIV
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testing among TB patients, increased coverage of co-
trimoxazole and isoniazid preventive therapy in HIV-1-
infected TB patients and earlier diagnosis of HIVand initiation
of antiretroviral therapy (ART) [2]. The increased accessibility
of ART has significantly improved the clinical outcome of
HIV-1 infected patients and reduces the TB risk by 58–80 %
[19]. The positive effects of ART have been described as
triphasic, starting with an early and rapid rise of CD45RO+
memory T cells that redistribute from lymphoid tissues into
the plasma within the first month of therapy, followed by a
reduction in T cell activation and improved CD4+ reactivity to
recall HIV-1 antigens, and finally the slower replenishment of
the CD45RA+ naïve Tcells [20]. In a longitudinal study of co-
infected patients sensitized byM. tuberculosis, ART led to an
increase in central memory (CD27+CD45RA− and
CD27+CCR5−CD4+) T cells by 12 weeks post-treatment,
followed by an increase in naïve (CD27+CD45RA+) T cells
at 36 weeks [21]. A separate longitudinal study confirmed that
the polyfunctional effector memory (CD27−CD45RO+) and
terminally differentiated memory (CD27−CD45RO−) CD4+
T cells responsive to mycobacterial purified protein derivative
(PPD) were restored 12 months post-ART [22].
Immune reconstitution inflammatory syndrome
Although ART has positive effects through suppression of
HIV-1 viral load and restoring CD4+ Tcell numbers, this rapid
restoration of the immune system can also lead to an undesir-
able complication known as immune reconstitution inflamma-
tory syndrome (IRIS; also known as immune restoration dis-
ease, IRD). IRIS is characterized by a transient but sometimes
severe local and systemic inflammatory response directed
against a known condition (e.g., opportunistic pathogens or
autoimmune diseases) in HIV-1 infected patients shortly after
ART initiation. It was first reported in 1992, where HIV-1 co-
infected patients developed Mycobacterium avium-complex
(MAC) disease with severe lymphadenopathy and high fever
following commencement of zidovudine monotherapy [23].
IRIS was subsequently documented to be associated with
many different pathogens, including cytomegalovirus
(CMV), hepatitis B and C viruses, Cryptococcus, and
M. tuberculosis, as well as in cancer (Kaposi’s sarcoma and
non-Hodgkin’s lymphoma) and autoimmune diseases [24].
In a meta-analysis on 54 cohort studies, Muller et al.
reviewed the incidence and mortality of IRIS associated with
different health conditions [25]. CMV-IRIS was found to have
the highest incidence (pooled estimates 37.7 %), while cryp-
tococcal meningitis-IRIS had the highest mortality (pooled
estimates 20.8 %). More recently, a meta-analysis on 40 stud-
ies indicates the overall incidence of IRIS is ~18 % among
patients with HIV-associated TB, withmortality attributable to
TB-IRIS of ~2 % [26]. Patients with TB meningitis (TBM),
however, are at high risk of developing IRIS (47 %), with a
mortality rate of up to 30 % following development of IRIS
[27–29].
Clinical definition of TB-IRIS
There is no diagnostic test for TB-IRIS and diagnosis there-
fore relies on medical history, laboratory data, and clinical
presentation. Prior to 2006, a number of TB-IRIS case defini-
tions existed [30–34], but the lack of consensus between these
definitions hindered clinical management and research on
IRIS. In response to the increase in incidence of this compli-
cation in resource-limited settings, over 100 researchers gath-
ered to agree consensus case definitions for ART-associated
TB and TB-IRIS [35], which have several times been re-
investigated prospectively and validated [36–39].
There are two forms of TB-IRIS that share clinical features
but are distinct in their temporal relationships between tuber-
culosis diagnosis and treatment and the initiation of ART:
paradoxical and unmasking. In paradoxical TB-IRIS, HIV-1-
patients are diagnosed with TB prior to ART commencement
and TB pathology has stabilized or improved during antitu-
bercular therapy. Following ART initiation, patients experi-
ence new, recurrent or worsening features of TB, such as
lymph node swelling and abscess formation, serositis, and
radiographic deterioration [35]. In unmasking TB-IRIS, pa-
tients with previously undiagnosed and untreated TB present
after initiation of ART and with often marked inflammatory
features of TB [35]. Exclusion criteria for both types of TB-
IRIS include exacerbation of TB due to drug-resistant
M. tuberculosis, presence of other opportunistic infections,
poor drug adherence, or adverse drug reactions.
Risk factors for TB-IRIS
Although the underlying mechanisms of TB-IRIS pathogene-
sis are incompletely elucidated, A few clinical risk factors
have been related to developing TB-IRIS. Firstly, patients
with low CD4+ T cell counts at the time of ART initiation,
followed by a rapid increase of CD4 counts post-ART, are
more likely to develop TB-IRIS [40–43]. This contributes to
an exaggerated T cell response directed to M. tuberculosis
along with overproduction of both pro- and anti-
inflammatory cytokines [44]. The second risk factor is a short
interval between starting antitubercular therapy and ART
[45–47]. The CD4 counts should be taken into consideration
when deciding the optimal time to initiate ART. For patients
with low CD4+ T cell counts (<50 cells/μl), the benefits of
early initiation of ART in reducingmortality and opportunistic
infections outweigh the risk of IRIS and therefore ARTshould
not be delayed more than 2 weeks. For those with CD4 counts
>50 cells/μl, ART should be commenced between 2 and 12
weeks after starting TB treatment. Furthermore, dissemination
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of TB infection to extrapulmonary organs appears to increase
the risk of TB-IRIS by up to eight-fold, probably due to higher
bacterial burden in such cases [48, 49]. TBM is the most
severe form of extrapulmonary TB and in one series
accounted for 12 % of all TB-IRIS cases [27]. Finally, high
HIV-1 viral load is another risk factor for TB-IRIS [26] and
M. tuberculosis culture positivity in the cerebrospinal fluid
(CSF) is a risk factor for TBM-IRIS [27].
Management
The inflammatory response associated with TB-IRIS can be
transient and may resolve without specific intervention. How-
ever, in many cases there is marked inflammation that, at
worst, may result in death. Anecdotal reports of glucocorti-
coids to reduce inflammation in TB-IRIS [50–52] encouraged
a randomized placebo-controlled trial to evaluate TB-IRIS
treatment with prednisone [53]. Patients with paradoxical
TB-IRIS who received a 4-week course of prednisone
(1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for
2 weeks) were found to have reduced need for hospitalization,
quicker resolution of symptoms and a better quality of life
without excess of severe adverse events, compared to those
who received placebo [53]. The beneficial effects of predni-
sone in reducing the inflammatory reactions in TB-IRIS were
associated with more rapid resolution of the elevated C-reactive
protein (CRP) and suppression of pro-inflammatory cytokines
of innate immune origin [54]. Nevertheless, prednisone should
be prescribed and monitored with caution in patients with ad-
vanced HIV-1 infection as (albeit outside the context of wide-
spread ART) it associates in some studies with an increase in
the risk of HIV-1 related malignancy (such as Kaposi’s sarco-
ma) and recurrent herpes zoster [55, 56]. Furthermore, as TB-
IRIS may occur in patients with drug-resistantM. tuberculosis,
prednisone therapy should be used with care pending satisfac-
tory optimization of antimicrobial therapy [57].
In addition to glucocorticoids, other anti-inflammatory
agents have also been used to treat TB-IRIS or IRIS associated
with other pathogens in isolated cases (Table 1). Non-steroidal
anti-inflammatory drugs (NSAIDs) have been used to relieve
symptoms in non-severe cases of paradoxical TB-IRIS,
MAC-IRIS, and cryptococcal-IRIS with lymphadenitis with
favorable results [58]. Thalidomide is an immunomodulatory
drug with use in cancer and inflammatory diseases. It has been
used to treat patients with intractable tuberculomas [59, 60]
and alleviated symptoms in steroid-refractory TB-IRIS, TB-
and cryptococcal-lymphadenitis IRIS, as well as in pediatric
neurological TB-IRIS [61–64]. Leukotriene antagonists (e.g.,
montelukast and zileuton) are used in treatment in asthma and
most recently have been proposed as potential host-directed
therapy in active TB [65]. Montelukast has been used to treat
two cases of steroid-refractory IRIS associated with TB and
syphilis and also in a patient with urticarial IRIS vasculitis,
with rapid clinical responses [66, 67]. Other drugs such as
Table 1 Drugs used to treat TB-IRIS
Drug/class of drugs Mechanism of action Potential side effects
Corticosteroids At gene level, activate the transcription of anti-inflammatory
mediators and inhibit transcription of pro-inflammatory
genes (e.g., cyclooxygenase and cytokines). At cellular
level, reduce the production of nitric oxide and inhibits
TCR signaling, thereby reducing cell migration,
proliferation and effector function
Increased risk of Kaposi’s sarcoma, herpes simplex
and zoster flare. General side effects include
increased risk of infections, hypertension, diabetes,
osteoporosis, ulcers and mental health problems
NSAIDs Relieve pain and reduce inflammation by inhibiting
cyclooxygenase-1 and −2, thereby reducing the synthesis
of inflammation mediator prostaglandins
Increased risk of gastrointestinal problems such as
ulcers; not recommended in patients with a history
of renal or liver disease
Thalidomide Modulates the production of cytokines and inflammatory
mediators; also stimulates T cells and modulates NK
cell cytotoxicity
Peripheral neuropathy, somnolence, hepatotoxicity,
teratogenicity, skin reactions, constipation, tremor,
mood changes and headache
Leukotriene receptor
antagonists
Blocks pro-inflammatory leukotrienes by inhibiting the
5-lipoxygenase pathway or by antagonizing
cysteinyl-leukotriene type 1 receptors; inhibit leukocytes
trafficking to the sites of antigen stimulation
Skin reaction, sinus pain, tremors, mood changes,
gastrointestinal problems; may also interact with
rifampicin and antiretroviral drugs
Pentoxifylline A non-selective adenosine receptor antagonist and also
non-selectively inhibits phosphodiesterase, resulting in an
increase in cAMP activity and reduced inflammation. In
addition, it improves erthyocytes deformability, decreases
blood viscosity and inhibits neutrophil adhesion and
activation
Hemorrhage, gastrointestinal problems, nausea,
dizziness, blurred vision, flushing and chest pain
Hydroxychloroquine Blocks activation through TLR and interferes with MHC-II
processing; reduce synthesis of pro-inflammatory cytokines
Blurred vision, somnolence, gastrointestinal problems,
skin rash and lost of appetite
Drugs with reported use in treating TB-IRIS, their mechanism of actions and side effects are listed
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pentoxifylline and hydroxychloroquine had also been used to
treat isolated cases of IRIS associated with different pathogens
with some reported benefits [68–71]. Nevertheless, these ther-
apies lack clinical trial data to assess their effectiveness and
potential adverse effects in treating TB-IRIS and further rig-
orous evaluations are required.
Finally, TNF-α inhibitors (infliximab, etanercept,
adalimumab ,or certolizumab pegol) are effective in treating
inflammation in rheumatoid arthritis, spondyloarthropathies,
and Crohn’s disease. While TNF-α inhibitors are to be pre-
scribed with caution in patients with latent TB due to in-
creased risk of reactivation, in one case withdrawal of
adalimumab led to a life-threatening paradoxical TB reaction
and the symptoms resolved when the patient was restarted on
adalimumab [72]. In another case study of steroid-refractory
TBM, the patient improved upon adalimumab therapy [73].
Similar observations have been reported with another TNF-α
inhibitor infliximab, where the patient suffered a debilitating
TB paradoxical reaction unresponsive to corticosteroids and
cyclophosphamide yet showed a favorable response following
three doses of infliximab given at monthly intervals [74]. In a
single case study with HIV-related inflammatory cerebral
cryptococcoma, patient had improved disease symptoms fol-
lowing treatment with adalimumab along with isoniazid and
pyridoxine (to prevent tuberculosis reactivation) [75]. Since
elevated levels of TNF-α are associated with TB-IRIS [76,
77], TNF-α inhibitors may offer potential benefits as treat-
ment for TB-IRIS.
Inflammatory reactions in TB-IRIS
TB-IRIS results from excessive inflammatory reactions
againstM. tuberculosis antigen driven by ART-induced recon-
stitution of the immune system [44, 78]. Numerous reports
have described aspects of the immune responses observed in
TB-IRIS, which we will discuss in detail in the following
sections.
CD4+ T cells and TCRγδ T cells
Paradoxical TB-IRIS was initially ascribed to acute expansion
of the mycobacteria-specific Th1 response following ART
commencement [44]. The first patient cohort study on TB-
IRIS consisted of 19 HIV-TB patients, 7 of whom developed
IRIS during the first month of ART. Compared to the non-
IRIS patients at 3 months, those with TB-IRIS were found to
have significantly higher number of IFN-γ-producing Th1
cells specific tomycobacterial PPD, but not toM. tuberculosis-
specific ESAT antigen or CMV [44]. Furthermore, peripheral
blood mononuclear cells (PBMC) from a subset of four pa-
tients (three TB-IRIS and one non-IRIS) were stimulated with
PPD antigen and those with TB-IRIS secreted significantly
higher concentrations of Th1 (IL-2, IL-12, IFN-γ, and IP-
10) and other (TNF-α, IL-1β, IL-6, IL-10, RANTES, and
MCP-1) cytokines and chemokines, while Th2 cytokines
(IL-4, IL-5, IL-13, and IL15) were not detected [44]. The
presence of M. tuberculosis antigen-specific Th1 expansions
in TB-IRIS was confirmed in a separate study of 95 HIV-TB
patients (35 TB-IRIS, 29 non-IRIS and 31 ART-naïve) [79].
However, not all cases of TB-IRIS were characterized by Th1
expansions and conversely expansions occurred longitudinal-
ly duringART inmany patients who did not develop TB-IRIS.
The proportion of HLA-DR+CD71+ CD4+ and CD8+ T cells
was similar in TB-IRIS and non-IRIS controls [79]. Two ad-
ditional studies by Tieu et al. [80] and Elliott et al. [81] utilized
interferon-gamma release assay (IGRA) and did not find any
difference in IFN-γ response in whole blood between patients
with paradoxical TB-IRIS and the non-IRIS controls 12weeks
post-ART, although the latter study observed an increase in
IFN-γ response to PPD 24 weeks post-ART.
Since IRIS commonly occurs in patients who are severely
lymphopenic following ART initiation, Sereti and colleagues
proposed that the syndrome is contributed by lymphopenia-
induced T cell homeostatic mechanisms, and an imbalance in
the regulatory mechanisms occurs irrespective of antigen
stimulus [82]. In a longitudinal study of 45 HIV-1-infected
patients commencing ART, 16 developed IRIS associated
with different etiological causes and were found to have a
highly activated, predominantly PD-1+ HLA-DR+ and Ki67+
CD4+ T cell phenotype prior to and during IRIS, compared to
the non-IRIS controls [82]. Moreover, these IRIS patients also
had a Th1/Th17-skewed cytokine profile upon polyclonal
stimulation and increased PD-1 and Ki67 expression in regu-
latory T cells (Treg), suggesting increased activation of effec-
tor T cells due to antigenic exposure. Furthermore, TB-IRIS
patients were found to have a significantly higher serum con-
centration of IL-7 and sCD25 compared to the non-IRIS con-
trols [82, 83], further indicating that TB-IRIS is associated
with exaggerated T cell activation and proliferation. In a
follow-up study, it was noted that patients with IRIS related
to different pathogens did not have a generalized T cell dys-
function and the dysregulated CD4+ Tcell response represent-
ed an upsurge of pre-existing responses that were both
polyfunctional and targeted exclusively to the opportunistic
pathogen, not to HIV-1 itself [84].
In addition to Th1, other T cell subsets have also been
investigated for their potential contribution to TB-IRIS. As
mentioned above, Foxp3+ CD4+ T cells (considered as Treg)
cells are critical in maintaining T cell homeostasis [85]. In
mice infected with TB, Treg cells expanded and accumulated
at the site of infection and contribute to suppression of Th1-type
immune responses [86]. Increased circulating Treg frequency
was also reported in TB patients, in which blood CD4+ T cells
were found to have increased cell surface expression of
CD25high and increased mRNA expression of Foxp3 [87].
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Several studies have investigated whether a dysregulated Treg
response may contribute to TB-IRIS and reported conflicting
results. Two of these studies found an expansion of Foxp3+
Tregs in M. avium and CMV-associated IRIS, although the
ability of these cells to secrete IL-10 appeared to be compro-
mised in vitro [88, 89]. Conversely Meintjes et al. reported an
overall low level of Foxp3+ T cells among PBMC, with no
difference in the percentage of these cells in TB-IRIS and
non-IRIS patients [79]. Similar observations were also reported
byAntonelli et al.: neither the number nor the frequency of Treg
differed when comparing IRIS to non-IRIS patients [82].
The role of TCRγδ T cells in TB-IRIS has also been ex-
plored. TCRγδ T cells are potent producers of IFN-γ and
TNF-α, possess cytotoxic capacity and release granule-
associated perforin and granzyme B to lyse infected cells upon
antigen recognition [90]. They are activated in response to
M. tuberculosis early after infection and may reduce intracel-
lular bacterial growth [91]. The Vδ2+TCRγδ+ T cell subset
are ascribed a role in adaptive immunity to mycobacterial
infection [92, 93] and their numbers are restored following
successful antitubercular treatment in HIV-1 infected persons
[94]. Patients co-infected with HIV-1 and M. tuberculosis,
however, have significantly reduced TCRγδ T cell responses
[91]. Compared to non-IRIS patients, those with paradoxical
TB-IRIS were found to have significantly higher number of
killer immunoglobulin receptor (KIR)−Vδ2+TCRγδ+ T cells
but a lower number of KIR+TCRγδ+ T cells at all timepoints
including baseline [95]. This observation indicates indepen-
dent regulation of different TCRγδ T cell subsets during IRIS
development, with the suggestion that the KIR−Vδ2+TCRγδ+
subset amplifies the dysregulated immune response to
M. tuberculosis, whereas the inhibitory KIR+Vδ2+TCRγδ+
subset was suppressed.
Together, these data demonstrate a role for CD4+ T cells
and other T cell subsets in the dysregulated inflammatory re-
sponse in TB-IRIS. Nevertheless, as some TB-IRIS cases are
not associated with T cell expansion, it remains conjectural
whether the T cell response is the cause, rather than the con-
sequence, of the syndrome.
CD8+ T cells
Compared to CD4+ T cells, there have been very limited stud-
ies on the role of CD8+ T cells in TB-IRIS pathogenesis. Two
studies showed that the numbers and frequency of CD8+ T
cells did not differ between TB-IRIS and non-IRIS patients
prior to ART and during IRIS [35, 96]. In contrast, Reyes-
Teran and colleagues reported that increased frequency of cir-
culating CD8+ T cells is a risk factor for developing IRIS
associated with M. tuberculosis and M. avium [97]. Further-
more, the authors reported an expansion of the naïve CD8+
subpopulation, as well as the CD38+ HLA-DR+ CD8+ Tcells,
during TB-IRIS episode [97]. No further phenotyping of the
CD8+ T cells in the study was performed, thus the precise
subpopulation associated with TB-IRIS development was
not defined. Furthermore, the functionality of CD8+ T cells
has not been investigated in the context of TB-IRIS and their
contribution to the syndrome remains unclear.
Soluble mediators
A feature of TB-IRIS is increased production of both pro- and
anti-inflammatory cytokines, which is in turn influenced by
the antigen load in patients [98, 99]. In the study by Tadokera
et al., PBMC from paradoxical TB-IRIS patients stimulated
with heat-killed M. tuberculosis secreted significantly higher
concentrations of IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p40,
IFN-γ, GM-CSF, and TNF-α, compared to those from the
non-IRIS controls [77]. Higher concentrations of IL-6, IL-8,
IL-10, IL-12p40, IFN-γ, and TNF-αwere also detected in the
serum of the same TB-IRIS patients. Similar observations
have been reported by others [100–102]. In a study comparing
TB-IRIS patients randomized to prednisone or placebo, the
serum concentration of IL-6, IL-10, IL-12p40, IFN-γ, IP-10,
and TNF-α decreased during 4 weeks of prednisone therapy,
but not in the placebo group [54], further implying a patho-
logical role for hypercytokinemia in TB-IRIS. IL-6 has been
suggested to be a major pathological mediator in TB-IRIS as a
higher level of plasma IL-6 and CRP at baseline was associ-
ated with subsequent development of TB-IRIS [103]. Barber
et al. assessed whether inhibition of IL-6 can reduce pathology
in a murine model with M. avium-associated IRIS (see
BAnimal model^ section) and showed that neutralization of
IL-6 with a monoclonal antibody reduced CRP levels, allevi-
ated disease pathology and extended survival [104]. Most re-
cently, Ravimohan et al. reported that inflammatory markers
increased rapidly in HIV-TB patients with early deaths and in
patients who developed TB-IRIS, but the two groups have
differential recovery of the adaptive immune system [76]. Pa-
tients with early mortality were found to have increased pre-
ART plasma concentrations of IL-6, IL-10, TNF-α, MCP-1,
and eotaxin, but these increases were not accompanied by
early recovery of CD4+ T cells. In contrast, the significant
increase in the plasma concentrations of IL-6 and TNF-α fol-
lowing ART initiation paralleled a marked increase in CD4
counts in TB-IRIS patients. Together, the CD4 counts prior to
and following ART, along with the concentrations of inflam-
matory markers such as IL-6 and TNF-αmight have potential
use as biomarkers to assist TB-IRIS diagnosis.
Furthermore, plasma or serum concentrations of IL-17 and
IL-22 have also been reported to be higher in both paradoxical
and unmasking TB-IRIS [100, 105]. Both IL-17 and IL-22
arise from distinct lineages of T cells and are critical in bridg-
ing innate and adaptive immunity in host defense against path-
ogens at mucosal sites (reviewed in [106]). More recently,
elevation of plasma IL-18 at baseline (pre-ART) and during
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TB-IRIS has also been reported [107, 108]. In addition to the
excessive release of both pro- and anti-inflammatory cyto-
kines, IP-10 and CCL4 chemokines were also found to be
elevated in the plasma of TB-IRIS patients longitudinally over
the course of ART [107, 109]. Similar findings were reported
in patients with TBM-IRIS, where the concentrations of an
array of chemokines (CXCL1-3, CCL2/3/4, and IP-10) were
all significantly higher in the CSF of TBM-IRIS patients com-
pared to non-IRIS TBM patients [110]. The induction of these
chemokines suggests an increased chemoattraction of
monocytes/macrophages and other immune cells to the site
of inflammation, thereby contributing to the pathogenesis of
TB-IRIS.
Other inflammatory mediators have also been reported to
be elevated in TB-IRIS.
Matrix metalloproteinases (MMPs) are zinc-dependent en-
dopeptidases involved in tissue repair, remodeling and modu-
lation of the immune response [111, 112]. The concentration
of MMP-1 was significantly higher in the lung of TB patients
with or without HIV-1 infection [113]. In the context of TB-
IRIS, PBMC from paradoxical TB-IRIS patients were found
to have significantly higher mRNA expression and protein
secretion of MMP-1, -3, -7 and -10 than in non-IRIS controls
[114]. Following prednisone therapy, the serum concentration
of MMP-7 showed a modest reduction, suggesting a specific
contribution to pathogenesis. Similarly, in the CSF of TBM-
IRIS patients, the concentration of MMP-9 was significantly
higher compared to non-IRIS TBMpatients both pre-ARTand
post-ART [110]. However, the CSF concentration of MMP-9
did not decrease following antitubercular and corticosteroid
therapy and continued to rise following ART initiation. This,
together with the poor clinical outcomes, suggests that more
potent and specific therapy may be needed for the manage-
ment of TBM-IRIS.
Finally, deficiency of vitamin D3 is associated with active
TB disease [115]. Adjunctive vitamin D3 supplementation can
help resolve TB pathology by suppressing antigen-stimulated
pro-inflammatory response and inhibiting secretion of MMP-
1, -7, -9 and -10 [116, 117]. While deficient plasma levels of
vitamin D3 did not predict the development of TB-IRIS [118],
serum concentrations of IL-1β, IL-6, and IL-8 were signifi-
cantly higher at both baseline and during TB-IRIS in vitamin
D3-deficient patients who experienced the syndrome [109].
In patients with TBM, concentrations of inflammatory me-
diators were significantly higher in the CSF than in blood
regardless of IRIS status [110]. Individuals who eventually
developed TBM-IRIS had elevated CSF concentrations of
an array of cytokines, chemokines, MMPs, as well as
neutrophil-associated mediators (e.g., S100A8/A9) at both
baseline and the time of symptom presentation [110]. Com-
pared to CSF, representative of the neurological compartment,
only subtle differences in the concentrations of these analytes
were detected in the corresponding blood samples between
TBM-IRIS and non-IRIS. Further studies conducted with ma-
terials from IRIS disease sites are likely to be informative.
The potential genetic influence in IRIS predisposition has
been investigated in two studies by Price and colleagues.
While the small sample size rendered these studies underpow-
ered and inconclusive, they nevertheless provided some
pointers that genetic factors might play a role in TB-IRIS. In
a study that included nine patients with MAC-associated IRIS
and two with TB-IRIS, the frequency of the IL6-174*C poly-
morphism (36%) was significantly lower than in the non-IRIS
controls (61–71 %) [119]. Furthermore, none of the IRIS pa-
tients carried the TNFA-308*2 polymorphism, while the fre-
quency was 23–52 % in the non-IRIS group. In a cohort study
with 17 Cambodian and 19 Indian patients, TB-IRIS was as-
sociated with higher frequencies of TNFA-1031*T and
SLC11A1 D543*G in Cambodian patients, while higher fre-
quencies of IL18-607*G andVDR Fokl(F/f)*Twere observed
in Indian patients [120]. Larger-scale studies would be re-
quired to determine with confidence if specific polymor-
phisms relate to the risk of TB-IRIS, although recruitment to
such a study might be difficult.
B cell response
TB-IRIS is regarded as a cell-mediated disease and little is
known about the role played by humoral immunity.
Simmoney et al. examined longitudinal antibody responses
in a cohort of 24 HIV-TB co-infected patients starting on
ART by measuring circulating free and immune-complexed
antibodies against M. tuberculosis antigens (ManLAM,
ESAT-6/CFP10, and PGL-Tb1) [121]. Compared to non-
IRIS patients, those with TB-IRIS had a significantly lower
level of anti-PGL-Tb1 antibody prior to the episode regardless
of CD4 counts or presence of complexed antibodies. There
was no difference in the antibody levels against ManLAM or
ESAT-6/CFP-10 between TB-IRIS and non-IRIS. A similar
result was also reported in another study where the levels of
anti-PPD, anti-ManLAM, and anti-38-kDa antigen antibodies
did not differ between TB-IRIS and non-IRIS patients prior to
ART, or at the time of IRIS [122]. Furthermore, the lineage of
M. tuberculosis did not appear to be associated with develop-
ment of TB-IRIS [121], although this interesting issue is not
resolved with certainty.
More recently, a regulatory role for B cells has been de-
scribed in TB granulomas in primates, which is mediated via
secretion of IL-10 and M. tuberculosis-specific antibodies
[123]. Antibodies contribute to immune defense through three
mechanisms: neutralization, activation of the complement sys-
tem, or opsonization. In opsonization, phagocytes expressing
Fcγ receptors recognize antibody-bound antigens (e.g.
M. tuberculosis) and take up the complex into the phagosomes
for elimination. Increased expression of Fcγ receptors
(FCGR1/2/3) has been reported in almost all transcriptional
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studies on active TB disease [124] and was also identified in
microarray profiling of TB-IRIS patients during the IRIS ep-
isode [125]. Together, these data suggest that humoral immu-
nity may also contribute to TB-IRIS pathogenesis, although
the precise mechanisms remain poorly defined.
Innate immune response
The role of innate immunity in TB-IRIS pathogenesis has
attracted increased attention in recent years. Myeloid cells
are the main cells targeted byM. tuberculosis and their pivotal
role in antimicrobial defense has been extensively described.
Colebunders and colleagues speculated that macrophages in
HIV-1 patients with advanced disease, particularly those co-
infected with M. tuberculosis, are inappropriately activated
[126]. Previous studies have reported that stimulation of
HIV-1 gp120 alone is sufficient to induce dysfunction and
aberrant gene expression in monocytes or monocytes-
derived macrophages [127–129]. During ART, these immu-
nosuppressive phenotypes are reversed and the functional re-
covery could result in excessive activation of the macrophages
by M. tuberculosis antigens [126], subsequently contributing
to development of IRIS. Lawn et al. later reported a fatal case
of unmasking TB-IRIS, in which CD68+ macrophages were
identified as the predominant inflammatory cells in postmor-
tem staining of lung tissue sections [130].
Human monocytes can be categorized into three different
subsets: classical CD14++CD16− and non-classical
CD14+CD16+ and CD14dimCD16+. The roles played by these
subsets in TB-IRIS have recently been explored. Peripheral
CD14+CD16+ monocytes were isolated from TB-IRIS and
non-IRIS patients and transcriptional profiling was performed.
Genes associated with the complement system and pattern
recognition receptors were found to be differentially abundant
in TB-IRIS [131, 132]. The authors further investigated the
role of complement in TB-IRIS and reported significantly
higher levels of C1q and C1-inhibitor of the classical pathway
at baseline and an imbalance in their ratio during TB-IRIS
onset at 2 weeks post-ART. Activation of the complement
system is known to trigger opsonization and killing of patho-
gens as well as recruitment of inflammatory cells [133]. In
another study that examined TB-IRIS patients from South
India and South Africa, TB-IRIS was associated with in-
creased plasma concentrations of sCD14, sCD163, and solu-
ble tissue factor, all of which are markers of monocyte activa-
tion [134]. Furthermore, patients with TB-IRIS lacked
CD14dimCD16+ monocytes while the frequency of
CD14++CD16− monocytes were significantly higher than in
non-IRIS patients. CD14++CD16− monocytes have high ex-
pression of the activation marker CD163 and were found to be
closely associated with plasma levels of systemic pro-
inflammatory markers CRP, IL-6, TNF-α, and soluble tissue
factor (CD142) prior to ART initiation and during TB-IRIS
[134]. Together, these data point towards a pathogenic role for
both classic and non-classical monocytes in TB-IRIS and the
mechanisms mediated by these cells should be investigated
further.
In addition to macrophages/monocytes, natural killer (NK)
cells and invariant natural killer T (iNKT) cells may also con-
tribute to TB-IRIS pathogenesis. Activated NK cells can pro-
tect against M. tuberculosis either directly by lysing infected
monocytes and antigen-specific Treg [135, 136], or indirectly
by restoring the frequency of M. tuberculosis-specific
CD8+IFN-γ+ T cells [137]. Patients with unmasking TB-
IRIS were found to have increased NK cell activation and
plasma concentrations of CRP and IL-8, compared to non-
IRIS or HIV-1-monoinfected controls [138]. In another cohort
of 128 co-infected patients from Cambodia, baseline NK cell
degranulation capacity was significantly higher in those who
eventually developed paradoxical TB-IRIS, but this difference
was abrogated following ART initiation, possibly due to reg-
ulatory feedback mechanisms or the internalization of NK
receptors following ligand binding [139]. Finally, microarray
analysis performed onM. tuberculosis-stimulated PBMC iso-
lated from patients identified an overabundance of granzyme
B and perforin transcripts in TB-IRIS, validated at the protein
level [96]. The increased secretion of perforin appeared to be
contributed by an increased number of CD3+Vα24+ iNKT
cells. Activation of CD1d-restricted iNKTcells has previously
been shown to protect mice fromM. tuberculosis infection via
a yet unknown mechanism [140]. Further studies are needed
to address the role of cytotoxic cells in TB-IRIS.
Neutrophils also appear to have a significant role in the
pathogenesis of the highly compartmentalized TBM-IRIS.
Active TB disease in HIV-1 uninfected persons is character-
ized by a type I interferon-inducible, neutrophil-driven
transcriptomic signature [141]. Mice lacking IFN1 receptor
were protected from TB-induced death with reduced recruit-
ment of neutrophils and inflammatory macrophages to the site
of infection [142]. In a cohort of HIV-1-infected South African
patients diagnosed with TBM, those who did not develop
TBM-IRIS but who were TB culture positive in their CSF
showed similar inflammatory response as the TBM-IRIS pa-
tients both at the time of TBM diagnosis and 2 weeks post-
ART [88]. However, TBM-IRIS was specifically associated
with elevated neutrophil counts in CSF and increased expres-
sion of the neutrophil mediators S100A8/9 [27, 110].
Most recently, we have employed transcriptomic profiling
of whole blood to investigate potential mechanisms that un-
derlie TB-IRIS pathogenesis. In a longitudinal study whose
endpoint was the development of TB-IRIS, we closely tracked
responses at various timepoints prior to and following ART
commencement (within days of starting ART and up to the
median time of IRIS occurrence at 2 weeks). We identified
transcripts of TLR signaling and activation of inflammasomes
to be prominent in the blood of TB-IRIS patients (Table 2)
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[125]. Both TLR2 and TLR4 have been shown to recognize
M. tuberculosis antigen. Mice lacking TLR4 have reduced
capacity to eliminate M. tuberculosis from the lungs and
succumbed to disease sooner than wild-type controls [143].
A separate mouse study showed that in high-dose aerosol
infection, TLR2 is critical in mediating innate defense against
M. tuberculosis infection [144]. Furthermore, TLR2 was
previously reported to express at higher baseline levels in
myeloid dendritic cells and monocytes in patients with para-
doxical and unmasking TB-IRIS, compared to non-IRIS, and
its expression remained higher even at 24 weeks post-ART
initiation [145]. This observation suggests that dysregulated
signaling via TLR2 mediates the inflammatory reactions ob-
served in TB-IRIS. Indeed, when we inhibited MyD88 (the
downstream adaptor of TLR2) in patient’s PBMC in vitro,
secretion of pro-inflammatory cytokines was markedly re-
duced specifically in TB-IRIS patients [125]. The production
of IL-1 in TB-IRIS appeared to be dependent on
Table 2 Canonical pathways associated with TB-IRIS
Top canonical pathways associated
with TB-IRIS
p value Regulation
Inflammasome activation 2.01E−04 Up
Toll-like receptor signaling 2.01E−04 Up
Endothelin-1 signaling 3.84E−04 Up
Role of pattern recognition receptors
in bacteria and virus recognition
8.83E−04 Up
IL-1 signaling 8.83E−04 Up
Microarray profiling using whole blood from a cohort of TB-IRIS and TB
non-IRIS patients was performed and differentially abundant transcripts
associated with TB-IRIS were identified. Functional analysis by Ingenu-
ity Pathway Analysis (IPA) indicates that these differentially abundant
transcripts overrepresented innate signaling pathways, including
inflammasome activation, toll-like receptor signaling and IL-1 signaling,
suggesting that innate immunity plays a significant role in TB-IRIS
pathogenesis
Fig. 1 Contrast-enhanced axial computed tomography (CT) image of
TBM-IRIS. CT image showing multiple ring-enhancing lesions with
surrounding edema and hydrocephalus in a 41-year-old woman. The
patient previously presented with TBM (CSF TB culture was positive
for M. tuberculosis susceptible to rifampicin and isoniazid) 10 weeks
prior to this presentation. At that time, she was started on TB treatment
and ART was initiated 9 weeks later. One week after initiating ART, the
patient developed recurrent headaches and this CT was performed
2 weeks later. The recurrent symptoms and these CT findings were
ascribed to TBM-IRIS and the patient was treated with corticosteroids
with symptom improvement. Image provided by Dr. Suzaan Marais
Fig. 2 A model of innate receptor signaling in mediating TB-IRIS path-
ogenesis. Microarray profiling revealed that TLR signaling and
inflammasome activation are critical in mediating TB-IRIS pathogenesis
(Table 2) [125]. Our proposed model begins withM. tuberculosis antigen
recognition by surface-expressing TLRs, which triggers the downstream
signaling cascade with adaptor molecules such as MyD88 and IRAK4 to
activate IRF7, thereby triggering the production of type I IFN. Paracrine
signaling of Type I IFN to IFNAR recruits and phosphorylates STAT1/2
dimers, leading to further recruitment of IRF9 and the formation of
ISGF3, thereby inducing pro-caspase-11 (caspase-4/5 in human) and
AIM-2 inflammasome (caspase-1). Caspase-11 cleaves IL-1α into its
mature form and can lead to pyroptosis. The noncanonical inflammasome
(caspase-11) can also activate the canonical inflammasome (caspase-1),
which cleaves IL-1β and IL-18 into their mature form. Alternatively,
TLR signaling via MyD88 can also activate NF-κb via the TAK1/IKK
complex. Activation of NF-κb triggers the production of an array of
cytokines, including TNF-α, IL-6 and IL-12. In addition, NF-κb can also
activates NLRP1/3 inflammasomes and subsequently leads to the produc-
tion of IL-1β and IL-18
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inflammasome activation. In vitro inhibition of Caspase-1/4/5
in PBMC fromTB-IRIS patients reduced IL-1 secretion, prob-
ably due to disruption in the cleavage from immature to ma-
ture form. Together, these data demonstrate the central role
played by innate receptor signaling in mediating TB-IRIS
pathogenesis and offer some mechanistic insights on the dis-
ease (Figs. 1 and 2).
Animal model
Since HIV-1 does not readily infect non-primates, studying
mycobacteria-associated IRIS in small animal models poses
a challenge. Thus far, only one murine model on IRIS has
been reported using a TCRα knockout mouse chronically in-
fected M. avium infection [146]. To recapitulate the CD4+ T
cell reconstitution observed in TB-IRIS patients, purified
CD4+ T cells from naïve mice were injected into T cell-
deficient M. avium-infected TCRα knockout mice, which
led to impaired lung function, severe wasting symptoms and
increased mortality within 3 weeks of T cell transfer. In
contrast, transfer of CD4+ T cells into wild-type chroni-
cally infected mice or TCRα knockout mice prior to
M. avium infection did not cause any disease. Unexpect-
edly, the nonlymphopenic OT-II mice were also found to
be susceptible to developing reconstitution disease in-
duced by transfer of M. avium-specific CD4+ T cells, in-
dicating that the reconstitution disease did not require a
lymphopenic environment. In addition, there were two- to
five-fold fewer donor CD4+ T cells recovered from infect-
ed compared with naïve recipients. Instead of spontaneous
proliferation of CD4+ T cells in T cell-deficient environ-
ment, the model was associated with impaired, rather than
exaggerated, T cell expansion. Furthermore, both antigen
recognition and secretion of IFN-γ by the grafted CD4+ T
cells were necessary for disease induction, which correlat-
ed with the large increase in the population of CD11b+
myeloid cells in the lungs and blood. While this model
recapitulates the CD4 restoration characteristic in IRIS, it
requires a high-dose of M. avium infection leading to bac-
terial burden that is very high. Furthermore, the model
does not capture the immunosuppressive phenotype of
monocytes and macrophages induced by HIV-1. Several
humanized mouse models have been developed for HIV-
1, some of which are able to support persistent viral in-
fection and gradual CD4+ T cells decline that mimics hu-
man infection [147]. Non-human primates which share
close physiology to humans have also been extensively
used to study HIV-1 and TB infection, but not yet applied
to TB-IRIS. While these models may better recapitulate
the overall immune aspects of TB-IRIS, the high cost of
performing such studies is a deterrent.
Concluding remarks
Although TB-IRIS was first described almost 20 years ago
with many subsequent case reports, the underlying mecha-
nisms that mediate the disease pathology remain to be fully
elucidated. There remains a lack of biomarkers to accurately
diagnose and track the syndrome, particularly in resource-
limited settings. The difficulty in studying the underlying
mechanisms of TB-IRIS pathogenesis is further complicated
by the absence of an animal model that can recapitulate dif-
ferent aspects of the immune defects observed in TB-IRIS, as
well as challenges, both practically and ethically, to recruit
appropriate controls groups: those who are infected only with
HIV-1 or TB, treated and untreated with ART and antituber-
cular drugs and healthy controls. While a set of consensus
guidelines adopted in recent years has helped to standardize
TB-IRIS diagnosis and treatment for systematic comparison,
our understanding on the pathogenesis remains incomplete.
Finally, although corticosteroids such as prednisone can
alleviate the symptoms and accelerate clinical improve-
ment, they also have undesirable side effects and drugs
targeting specific pathological pathways should be ex-
plored. Our group and others have recently utilized
transcriptomic approaches to study the underlying mech-
anisms mediating TB-IRIS and the results from these
studies offered insights on some of the immunological
pathways involved that may guide future directions for
host-directed therapy.
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